What is KeyCorp’s Forecast for Solventum FY2026 Earnings?

Solventum Corporation (NYSE:SOLV) – KeyCorp cut their FY2026 earnings per share (EPS) estimates for Solventum in a report issued on Sunday, January 25th. KeyCorp analyst B. Fishbin now expects that the company will post earnings per share of $6.20 for the year, down from their prior estimate of $6.30. KeyCorp has a “Overweight” rating and a $97.00 price target on the stock. The consensus estimate for Solventum’s current full-year earnings is $6.58 per share.

Other equities analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Mizuho set a $100.00 price objective on Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Zacks Research cut Solventum from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 1st. BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Tuesday, December 2nd. Finally, Stifel Nicolaus upped their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $90.83.

Solventum Trading Down 1.3%

Shares of SOLV opened at $76.60 on Wednesday. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. Solventum has a 12-month low of $60.70 and a 12-month high of $88.20. The firm has a 50-day moving average price of $81.70 and a 200 day moving average price of $75.78. The firm has a market capitalization of $13.29 billion, a P/E ratio of 8.83, a P/E/G ratio of 7.12 and a beta of 0.34.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The company had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same period in the prior year, the business earned $1.64 EPS. The firm’s quarterly revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS.

Institutional Investors Weigh In On Solventum

A number of institutional investors have recently modified their holdings of the company. Assetmark Inc. lifted its stake in Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after acquiring an additional 128 shares in the last quarter. Hilltop National Bank increased its stake in Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares during the period. Allworth Financial LP lifted its position in shares of Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC boosted its stake in shares of Solventum by 0.5% in the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after purchasing an additional 134 shares during the period. Finally, BOKF NA increased its stake in Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after buying an additional 141 shares during the period.

Solventum announced that its board has initiated a share buyback program on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 7.5% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.